|
|
|
|
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Ovarian Cancer to include two additional combination treatment regimens for women with select types of recurring ovarian cancer FORT WASHINGTON, Pa.--(BUSINESS WIRE)--Jan...
|
|
|
NCCN updates the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer to reflect the addition of two preferred combination regimens for a specific cohort of patients based on data from recent...
|
|
|
Two Combination Treatment Regimens Added To Updated NCCN Guidelines For Ovarian Cancer
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer to reflect the addition of two preferred combination regimens for a specific cohort of patients based on data from recent...
|
|
|
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
FORT WASHINGTON, PA - The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer to reflect the addition of two preferred combination regimens for a specific cohort of patients based...
|
|
|
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
The National Comprehensive Cancer Network ( NCCN : ) recently updated the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer to reflect the addition of two preferred combination regimens for a specific cohort of patients based on data from recent...
|
|
|
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); FORT WASHINGTON, Pa.- (Business Wire) The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer to reflect the...
|
|
|
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Ovarian Cancer to include two additional combination treatment regimens for women with select types of recurring ovarian cancer FORT WASHINGTON, Pa.--(BUSINESS WIRE)--The...
|
|
|
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Ovarian Cancer to include two additional combination treatment regimens for women with select types of recurring ovarian cancer FORT WASHINGTON, Pa.(BUSINESS WIRE) The...
|
|
|
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Ovarian Cancer to include two additional combination treatment regimens for women with select types of recurring ovarian cancer The National Comprehensive Cancer Network ...
|
|
|
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
FORT WASHINGTON, Pa.- (BUSINESS WIRE) - The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer to reflect the addition of two preferred combination regimens for a specific...
|
|
|
Bonding with BIND Biosciencess New CEO Scott Minick
[] Scott Minick made his official debut as CEO of BIND Biosciences Monday at the JP Morgan Healthcare Conference in San Francisco, which makes for one of the most frenetic weeks of the year for biotech chiefs.The Cambridge, MA-based startup also made some...
|
|
|
Bonding with BIND Biosciencess New CEO Scott Minick
Life Sciences , ceos , people Ryan McBride wrote: [ Clarified and Corrected---7:30 AM, 01/15/10 ] Scott Minick made his official debut as CEO of BIND Biosciences Monday at the JP Morgan Healthcare Conference in San Francisco, which makes for one of the most...
|
|
|
VC Scott Minick Named CEO of BIND Bioscience
Scott Minick has stepped down as a managing director with Arch Venture Partners , in order to become president and CEO of Arch portfolio company BIND Biosciences.In related news, BIND has raised $11 million in third-round funding, from Arch, Flagship...
|
|
|
Bind Biosciences raises $11M venture round
Boston Business Journal - by Send this story to a friend address of friend (insert comma between multiple addresses): Your email address: Add a brief note: Enter words from the security image above: reCAPTCHA Related Drug developer has raised $11 million in a...
|
|
|
Bind Biosciences raises $11M, appoints CEO
Bind Biosciences, a Cambridge nanoparticle-based drug developer co-founded by MITs Robert Langer and Harvard Medical Schools Omid Farokhzad, has raised $11 million in a third round of financing, according to a company spokeswoman.The company also announced...
|
|
|
BIND Biosciences Appoints Scott Minick as President and CEO
BIND Biosciences announced today the appointment of Scott Minick as President and CEO.Minick was formerly a Managing Director at , a major BIND investor, and previously the President and COO of SEQUUS Pharmaceuticals/Liposome Technology Inc., where he led...
|
|
|
BIND Biosciences Appoints Scott Minick as President and CEO
Last update: 12:30 PM State-by-State AND City-by-City FreshNews.com Delivers Company Tech News U.S.States: Appoints as President and CEO - - Submitted by admin on 1/11/2010 @ 1:21 PM Companies mentioned in this article: CAMBRIDGE, Mass. -- (BUSINESS WIRE) ...
|
|
|
BIND Biosciences Appoints Scott Minick as President and CEO
BusinessWire - BIND Biosciences announced today the appointment of Scott Minick as President and CEO.Minick was formerly a Managing Director at ARCH Venture Partners, a major BIND investor, and previously the President and COO of SEQUUS Pharmaceuticals...
|
|
|
BIND Biosciences Appoints Scott Minick as President and CEO
High-Precision Therapeutics through Medicinal NanoengineeringTM CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences announced today the appointment of Scott Minick as President and CEO.Minick was formerly a Managing Director at , a major BIND investor, and...
|
|
|
BIND Biosciences Appoints Scott Minick as President and CEO
High-Precision Therapeutics through Medicinal NanoengineeringTM CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Biosciences announced today the appointment of Scott Minick as President and CEO.Minick was formerly a Managing Director at ARCH Venture Partners, a...
|
|
|
BIND Biosciences Appoints Scott Minick as President and CEO
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); CAMBRIDGE, Mass.- (Business Wire) BIND Biosciences announced today the appointment of Scott Minick as President and CEO. Minick was formerly a Managing Director at , a major BIND investor, and...
|
|
|
BIND Biosciences Appoints Scott Minick as President and CEO
CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences announced today the appointment of Scott Minick as President and CEO.Minick was formerly a Managing Director at , a major BIND investor, and previously the President and COO of SEQUUS Pharmaceuticals...
|
|
|
BIND Biosciences Appoints Scott Minick as President and CEO
High-Precision Therapeutics through Medicinal Nanoengineering CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences announced today the appointment of Scott Minick as President and CEO.Minick was formerly a Managing Director at ARCH Venture Partners, a major...
|
|
|
BIND Biosciences Appoints Scott Minick as President and CEO
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); CAMBRIDGE, Mass.- (Business Wire) BIND Biosciences announced today the appointment of Scott Minick as President and CEO. Minick was formerly a Managing Director at , a major BIND investor, and...
|
|
|
BIND Biosciences Appoints Scott Minick as President and CEO
BIND Biosciences : announced today the appointment of Scott Minick : as President and CEO.Minick was formerly a Managing Director at ARCH Venture Partners, a major BIND investor, and previously the President and COO of SEQUUS Pharmaceuticals/Liposome...
|
